The Efficacy of Qianglidingxuan Tablets in the Treatment of Hypertension
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Qianglidingxuan Tablets in the Treatment of Mild to Moderate Essential Hypertension With Hyperactivity of Liver Yang
Sponsor: Guang'anmen Hospital of China Academy of Chinese Medical Sciences
A PHASE4 clinical study on Hypertension and Medicine, Chinese Traditional, this trial is completed. The trial is conducted by Guang'anmen Hospital of China Academy of Chinese Medical Sciences and has accumulated 3 data snapshots since 2021. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
3 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE4
First recorded
Mar 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences
- Jilin Provincial Hospital of Traditional Chinese Medicine, Affiliated Hospital of Changchun University of Traditional Chinese Medicine
- The First Affiliated Hospital of Henan University of Traditional Chinese Medicine
- The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine
- Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine
For direct contact, visit the study record on ClinicalTrials.gov .